Crestor (Rosuvastatin) and Hormonal Contraceptives: Drug Interaction Guide

Rosuvastatin (brand name Crestor, an HMG-CoA reductase inhibitor, or statin) is not contraindicated with combined hormonal contraceptives. The FDA-approved label reports that co-administering rosuvastatin with a combined oral contraceptive raises blood levels of the contraceptive hormones, not the reverse, and this article draft is pending qualified clinical review before publication.

The direct answer

Rosuvastatin (Crestor) and combined hormonal contraceptives containing ethinyl estradiol can generally be used together. According to the FDA-approved Crestor label, a study using rosuvastatin 40 mg with an oral contraceptive containing ethinyl estradiol 0.035 mg and norgestrel 0.180 mg found ethinyl estradiol AUC increased by about 26% and norgestrel AUC increased by about 34%. This is documented pharmacokinetic evidence, not an observational estimate. The effect runs in one direction, meaning contraceptive hormone exposure rises while rosuvastatin's own levels and lipid-lowering activity are not meaningfully affected. No routine dose change is recommended for either medication, and the interaction has not been formally studied at rosuvastatin doses below 40 mg or with non-oral hormonal methods, which matters for anyone trying to generalize beyond the exact study conditions.

What the label study actually showed

The FDA-approved Crestor prescribing information describes the interaction using the specific combination and dose above. That is the only condition with formal human pharmacokinetic data behind it. Extending the finding to other rosuvastatin doses, other contraceptive formulations, or other delivery routes is a reasonable inference, not a demonstrated fact, and the sections below try to keep that distinction visible.

Rosuvastatin is metabolized only to a limited extent by cytochrome P450 enzymes and has little affinity for CYP3A4, which is the pathway responsible for many other statin-hormone interactions (for example, with atorvastatin and simvastatin). Because of this, the mechanism behind rosuvastatin's effect on estrogen and progestin levels is generally attributed in the pharmacology literature to competition at hepatic uptake transporters such as OATP1B1 and BCRP, which also participate in hormone clearance. This mechanistic explanation is plausible and consistent with rosuvastatin's known transporter-dependent elimination, but it is a mechanistic inference rather than a directly proven pathway for this specific interaction, and a reader who needs the underlying transporter studies should ask a pharmacist or clinician to verify the primary literature before treating it as settled.

A 26% rise in ethinyl estradiol exposure is a meaningful pharmacokinetic change but not an unusual one in absolute terms; contraceptive bioequivalence standards tolerate comparable variability between formulations. It does not lower contraceptive efficacy. If anything, higher hormone exposure would be expected to reinforce ovulation suppression rather than weaken it.

How interaction databases classify it

Commercial drug interaction references such as Lexicomp and Micromedex are commonly used by pharmacists to triage interactions, and this combination is typically flagged at a "monitor" or "moderate" level rather than as contraindicated or high severity. These are proprietary classification systems without a single public citation, so the exact wording and rating should be confirmed against the reference your pharmacy or clinic actually uses rather than assumed from this summary.

No published case series specifically linking this drug pair to venous thromboembolism, breakthrough bleeding, or contraceptive failure was identified for this draft. Absence of reported cases is reassuring but is not the same as a controlled safety study, and it should be described that way rather than as proof of safety.

Why statins and hormonal contraceptives are often prescribed together

Statins and hormonal contraceptives share a patient population more often than either drug's individual label would suggest. Women diagnosed with familial hypercholesterolemia, or with other cardiovascular risk factors requiring early statin therapy, often start treatment during their reproductive years, which is exactly when reliable contraception matters most. Familial hypercholesterolemia is relatively common; guideline bodies have cited estimates in the range of roughly 1 in 200 to 1 in 300 people for the heterozygous form, though the exact figure varies by population and should be verified against a current guideline before being repeated as a fixed number.

All statins, including rosuvastatin, carry an FDA pregnancy contraindication because decreased cholesterol synthesis may affect fetal development. This creates a real clinical need: a woman taking rosuvastatin who does not want to become pregnant needs effective contraception, and telling her to avoid hormonal methods solely because of a 26% pharmacokinetic increase would remove a well-tolerated option without a clear safety justification.

Does the rosuvastatin dose change the picture?

The FDA label's pharmacokinetic study used rosuvastatin 40 mg, the maximum approved dose. Rosuvastatin's pharmacokinetics are approximately linear across the 5 mg to 40 mg range, which supports the general expectation that lower doses would produce a smaller hormone-level increase. That expectation has not been confirmed by a dedicated interaction study at 5, 10, or 20 mg, which are the doses most patients actually take. Treat the following table as a reasoned extrapolation, not as measured data.

How this compares with other statins

Atorvastatin's label similarly documents an increase in ethinyl estradiol and norethindrone exposure when co-administered with oral contraceptives, per the FDA-approved Lipitor label. The magnitude reported there is broadly similar to rosuvastatin's, but the mechanism differs: atorvastatin and simvastatin are CYP3A4 substrates, so a CYP3A4 inhibitor (certain antifungals, macrolide antibiotics, grapefruit juice) can compound their interaction with estrogen in a way that would not apply to rosuvastatin, since rosuvastatin bypasses CYP3A4 almost entirely. For a patient already taking a CYP3A4 inhibitor for another condition, this mechanistic difference is a genuine reason a prescriber might prefer rosuvastatin over atorvastatin, independent of lipid-lowering potency.

Pravastatin and pitavastatin also have minimal CYP450 metabolism, similar to rosuvastatin, but formal interaction data with oral contraceptives is limited for both. Simvastatin has not been confirmed by a dedicated published interaction trial with oral contraceptives, though a CYP3A4-mediated effect similar to atorvastatin's would be expected on mechanistic grounds.

What about non-oral hormonal contraceptives?

The labeled pharmacokinetic data apply specifically to a combined oral contraceptive taken by mouth. No formal interaction studies were identified for rosuvastatin with the transdermal patch, the vaginal ring, the hormonal IUD, the etonogestrel implant, or injectable depot medroxyprogesterone.

This matters because oral contraceptives undergo first-pass hepatic metabolism before reaching systemic circulation, while transdermal and vaginal ring delivery largely bypass that step. If rosuvastatin's effect depends on competition at hepatic transporters during first-pass processing, non-oral routes might be affected less. That is a plausible hypothesis based on pharmacology, not an established finding, and it should not be presented to a patient as proven.

Progestin-only methods (hormonal IUD, implant, the injection) do not contain ethinyl estradiol, and the labeled interaction was measured using ethinyl estradiol and norgestrel specifically, so it does not directly describe progestin-only exposure. The labeling for levonorgestrel intrauterine systems describes minimal systemic absorption with local uterine hormone release, which makes a clinically meaningful transporter-level interaction with rosuvastatin less likely, though this has not been directly tested. For patients who want to avoid the question entirely, a hormonal IUD or implant also carries a substantially lower typical-use failure rate than the pill, patch, or ring, according to CDC contraceptive effectiveness information.

What to monitor, and what not to worry about

No routine laboratory monitoring is recommended specifically for this interaction. The standard lipid panel schedule (baseline, then 4 to 12 weeks after starting or changing therapy, then periodically) applies regardless of contraceptive use.

Estrogen-containing contraceptives have been reported in the broader literature to raise triglycerides in some women, independent of any statin. If triglycerides rise unexpectedly in a patient on both medications, that contraceptive effect should be considered before assuming the statin is underperforming or escalating the dose. The exact magnitude of that estrogen-driven triglyceride effect varies across studies and populations, and a specific percentage should be confirmed against current literature rather than quoted as a fixed number.

Symptoms worth reporting between visits include new or worsening headaches, especially migraine with aura, new breast tenderness, nausea, or a clear change in menstrual bleeding pattern after starting or changing statin therapy. These are nonspecific and do not confirm the interaction is responsible, but they are the signals a clinician would want to know about.

When switching contraception or statin makes sense

Switching either medication because of this interaction alone is rarely necessary. A few situations are worth a conversation with a prescriber:

New estrogen-related symptoms after starting rosuvastatin. If breast tenderness, worsened migraines, or clear cycle changes appear soon after starting or increasing rosuvastatin, a lower-dose ethinyl estradiol formulation (for example, 20 mcg products) is a reasonable option to discuss, since the interaction scales with whatever baseline estrogen dose is present.

Existing VTE risk factors. Women with obesity, a personal or strong family history of venous thromboembolism, known clotting disorders, or who are over 35 and smoke are already at elevated baseline risk with combined hormonal contraception. The ACOG practice bulletin on hormonal contraception in women with coexisting medical conditions generally advises against combined hormonal methods in women with multiple VTE risk factors, independent of statin use. In these patients, a progestin-only or non-hormonal method is usually preferred, and the rosuvastatin interaction is a minor consideration next to that baseline risk.

Other estrogen-raising medications on the list. If a patient is also taking a drug independently known to raise ethinyl estradiol exposure, the combined effect with rosuvastatin could be additive. A full medication review is more useful here than focusing on the rosuvastatin-contraceptive pair in isolation.

Evidence boundary

Established: Rosuvastatin 40 mg increases ethinyl estradiol and norgestrel AUC by the amounts documented in the FDA-approved Crestor label when co-administered with the specific oral contraceptive studied. This is a one-directional pharmacokinetic effect. All statins, rosuvastatin included, are contraindicated in pregnancy.

Plausible but unproven: That the interaction is smaller at rosuvastatin doses below 40 mg. That non-oral hormonal contraceptive routes (patch, ring, IUD, implant, injection) produce a smaller or absent interaction because they bypass first-pass hepatic metabolism. That the mechanism is specifically OATP1B1/BCRP transporter competition.

Not established: Any formally measured interaction magnitude for rosuvastatin at 5, 10, or 20 mg with oral contraceptives. Any formally measured interaction with a non-oral hormonal contraceptive. Any case-level evidence linking this specific drug pair to thromboembolism, breakthrough bleeding, or contraceptive failure. A precise, universally applicable estimate of how much estrogen-containing contraceptives raise triglycerides.

Evidence-status interaction assessment

Use this to see, at a glance, which parts of the rosuvastatin-contraceptive question are backed by label data versus reasoned extrapolation, and what a clinician or pharmacist should independently verify before making a decision.

Patient counseling points

• Contraceptive efficacy is not reduced by this interaction; hormone levels rise, they do not fall.
• The labeled data reflect the highest approved rosuvastatin dose (40 mg); most patients take 10 or 20 mg, where the effect is expected to be smaller but has not been separately measured.
• Report new headaches, breast tenderness, or unusual bleeding patterns after starting or changing either medication.
• Pregnancy must be avoided while taking any statin; if contraception is being stopped or changed, the prescriber should be told so statin therapy can be reassessed.
• Long-acting reversible methods (IUD, implant) have not been formally studied with rosuvastatin but are not expected to carry the same oral first-pass interaction, and they also have lower typical-use failure rates than the pill.